Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Patients with HER2-low breast cancer have limited targeted treatment options for progressing disease after primary therapy. An antibody-drug conjugate has shown efficacy in early trials.
New research findings are summarized in a short video.
To see the full article, follow this link: nej.md/3aCIH6d

[@user-lb2yv9yr4r]

Как перевести на русский язык?